Valuation: Nutriband Inc.

Market Cap 88.49M 78.63M 73.38M 66.89M 126M 8.51B 127M 888M 344M 4.35B 332M 325M 13.96B P/E 2025
-8.39x
P/E 2026 -1.86x
Enterprise Value 84.16M 74.78M 69.79M 63.62M 120M 8.09B 121M 845M 327M 4.14B 316M 309M 13.27B EV / Sales 2025
41.1x
EV / Sales 2026 26.5x
Free-Float
40.85%
Yield 2025 *
-
Yield 2026 -
1 day-1.09%
1 week-9.00%
Current month-3.19%
1 month+29.31%
3 months+137.91%
6 months+100.55%
Current year+60.35%
1 week 7.25
Extreme 7.25
8.99
1 month 5.46
Extreme 5.46
9.19
Current year 2.8
Extreme 2.8
9.19
1 year 2.8
Extreme 2.8
9.19
3 years 1.53
Extreme 1.53
11.78
5 years 1.53
Extreme 1.53
11.78
10 years 0.86
Extreme 0.857142
43.54
Manager TitleAgeSince
Chief Executive Officer 35 2015-12-31
Chief Executive Officer 52 -
Director of Finance/CFO 77 2020-09-01
Director TitleAgeSince
Chairman 52 2022-01-20
Director/Board Member 48 2018-06-30
Director/Board Member 38 2018-06-30
Date Insider Type Main position Quantity % Market Cap. Importance
1/31/25 Other

Founder

126,833 1.1420%
1/31/25 Option

Chief Financial Officer

212,837 1.9164%
3/20/24 Free

Chief Financial Officer

162,500 2.0745%
Change 5-day change 1-year change 3-year change Capi.($)
-1.09%-9.00%-2.02%+206.46% 88.49M
+0.84%-3.74%-27.56%+1.79% 169B
-0.07%-2.55%-11.59%+12.86% 110B
+0.90%+1.13%-25.66%+3.60% 106B
-1.24%-0.76%-49.50%-12.08% 73.87B
-0.24%+0.69%+2.08%+71.44% 58.98B
-0.86%+2.96%+12.91%+61.58% 51.28B
-0.71%-3.82%-8.68%-31.71% 48.16B
+0.12%-0.17%-17.87%+21.91% 40.84B
-1.01%-1.45%+27.31%-6.14% 32.21B
Average -0.34%-1.67%-10.06%+32.97% 69.03B
Weighted average by Cap. +0.03%-1.30%-17.07%+11.25%

Financials

2025 2026
Net sales 2.14M 1.9M 1.77M 1.62M 3.05M 206M 3.08M 21.47M 8.32M 105M 8.03M 7.86M 337M 2.04M 1.81M 1.69M 1.54M 2.9M 196M 2.93M 20.44M 7.92M 100M 7.65M 7.48M 321M
Net income -10.48M -9.31M -8.69M -7.92M -14.94M -1.01B -15.08M -105M -40.76M -515M -39.36M -38.5M -1.65B -8.23M -7.31M -6.82M -6.22M -11.73M -791M -11.84M -82.59M -32M -404M -30.9M -30.23M -1.3B
Net Debt -4.13M -3.67M -3.42M -3.12M -5.88M -397M -5.94M -41.4M -16.04M -203M -15.49M -15.15M -651M -4.33M -3.85M -3.59M -3.27M -6.17M -416M -6.23M -43.45M -16.84M -213M -16.25M -15.9M -683M
Logo Nutriband Inc.
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Employees
-
Date Price Change Volume
26-10-02 US$7.280 -1.09% 47,045
26-10-01 US$7.360 -2.13% 42,174
26-09-30 US$7.520 -8.85% 147,736
26-09-29 US$8.250 +0.24% 140,525
26-09-28 US$8.230 +2.88% 284,818
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
7.280USD
Average target price
15.00USD
Spread / Average Target
+106.04%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NTRB Stock